scholarly journals The Frequency and Self-perceived Impact on Daily Life of Motor and Non-motor Symptoms in Cervical Dystonia

2017 ◽  
Vol 4 (5) ◽  
pp. 750-754 ◽  
Author(s):  
Marenka Smit ◽  
Anna L. Bartels ◽  
Anouk Kuiper ◽  
Arwen S. J. Kamphuis ◽  
Vladimir Han ◽  
...  
Keyword(s):  
Cervical Dystonia ◽  
Daily Life ◽  
Motor Symptoms ◽  
Perceived Impact ◽  
Non Motor Symptoms

scholarly journals Non-motor symptoms in cervical dystonia: A concept in evolution

2020 ◽  
Vol 23 (4) ◽  
pp. 428
Author(s):  
Daniele Urso ◽  
Valentina Leta ◽  
KRay Chaudhuri
Keyword(s):  
Cervical Dystonia ◽  
Motor Symptoms ◽  
Non Motor Symptoms

scholarly journals Prevalence of non‐motor symptoms and their association with quality of life in cervical dystonia

2020 ◽  
Vol 142 (6) ◽  
pp. 613-622
Author(s):  
Vladimir Han ◽  
Matej Skorvanek ◽  
Marenka Smit ◽  
Monika Turcanova Koprusakova ◽  
Tialda Hoekstra ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cervical Dystonia ◽  
Motor Symptoms ◽  
Non Motor Symptoms

scholarly journals NON-MOTOR SYMPTOMS OF CERVICAL DYSTONIA

2018 ◽  
Vol 3 (63) ◽  
pp. 10-12
Author(s):  
T.Y. Avseitseva ◽  
◽  
A.F. Ivolgin
Keyword(s):  
Cervical Dystonia ◽  
Motor Symptoms ◽  
Non Motor Symptoms

scholarly journals Non-motor symptoms in cervical dystonia: A review

2020 ◽  
Vol 0 (0) ◽  
pp. 0
Author(s):  
Ravi Yadav ◽  
Somdattaa Ray ◽  
PramodKumar Pal
Keyword(s):  
Cervical Dystonia ◽  
Motor Symptoms ◽  
Non Motor Symptoms

scholarly journals Effect of Botulinum Toxin on Non-Motor Symptoms in Cervical Dystonia

Toxins ◽  
2021 ◽  
Vol 13 (9) ◽  
pp. 647
Author(s):  
Matteo Costanzo ◽  
Daniele Belvisi ◽  
Isabella Berardelli ◽  
Annalisa Maraone ◽  
Viola Baione ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Sleep Disorders ◽  
Clinical Assessment ◽  
Cervical Dystonia ◽  
Time Course ◽  
Motor Symptom ◽  
Symptom Improvement ◽  
Motor Symptoms ◽  
Psychiatric Disturbances ◽  
Non Motor Symptoms

Patients with cervical dystonia (CD) may display non-motor symptoms, including psychiatric disturbances, pain, and sleep disorders. Intramuscular injection of botulinum toxin type A (BoNT-A) is the most efficacious treatment for motor symptoms in CD, but little is known about its effects on non-motor manifestations. The aim of the present study was to longitudinally assess BoNT-A’s effects on CD non-motor symptoms and to investigate the relationship between BoNT-A-induced motor and non-motor changes. Forty-five patients with CD participated in the study. Patients underwent a clinical assessment that included the administration of standardized clinical scales assessing dystonic symptoms, psychiatric disturbances, pain, sleep disturbances, and disability. Clinical assessment was performed before and one and three months after BoNT-A injection. BoNT-A induced a significant improvement in dystonic symptoms, as well as in psychiatric disturbances, pain, and disability. Conversely, sleep disorders were unaffected by BoNT-A treatment. Motor and non-motor BoNT-A-induced changes showed a similar time course, but motor improvement did not correlate with non-motor changes after BoNT-A. Non-motor symptom changes after BoNT-A treatment are a complex phenomenon and are at least partially independent from motor symptom improvement.

scholarly journals Emotional well-being and pain could be a greater determinant of quality of life compared to motor severity in cervical dystonia

2020 ◽  
Author(s):  
Lisa Klingelhoefer ◽  
Maximilian Kaiser ◽  
Anna Sauerbier ◽  
Robert Untucht ◽  
Miriam Wienecke ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Cervical Dystonia ◽  
Economic Status ◽  
Demographic Data ◽  
Well Being ◽  
Motor Symptoms ◽  
Related Quality ◽  
Health Related ◽  
Non Motor Symptoms

Abstract Non-motor symptoms (NMS) occur in patients with cervical dystonia (CD) but with variable frequencies and impact on health-related quality of life (HRQoL). To define non-motor and motor profiles and their respective impact on HRQoL in CD patients using the newly validated Dystonia Non-Motor Symptoms Questionnaire (DNMSQuest). In an observational prospective multicentre case–control study, we enrolled 61 patients with CD and 61 age- and sex-matched healthy controls (HC) comparing demographic data, motor and non-motor symptoms and HRQoL measurements. 95% CD patients reported at least one NMS. Mean total NMS score was significantly higher in CD patients (5.62 ± 3.33) than in HC (1.74 ± 1.52; p < 0.001). Pain, insomnia and stigma were the most prevalent NMS and HRQoL was significantly impaired in CD patients compared to HC. There was strong correlation of NMS burden with HRQoL (CDQ-24: r = 0.72, EQ-5D: r = − 0.59; p < 0.001) in CD patients. Regression analysis between HRQoL and NMS suggested that emotional well-being (standardized beta = − 0.352) and pain (standardized beta = − 0.291) had a major impact on HRQoL while, in contrast motor severity had no significant impact in this model. Most NMS with the exception of pain, stigma and ADL did not correlate with motor severity. NMS are highly prevalent in CD patients and occur independent of age, sex, disease duration, duration of botulinum neurotoxin therapy and socio-economic status. Specific NMS such as emotional well-being and pain have a major impact on HRQoL and are more relevant than motor severity.

scholarly journals The Parkinson’s Real-World Impact Assessment (PRISM) Study: A European Survey of the Burden of Parkinson’s Disease in Patients and their Carers

2021 ◽  
pp. 1-15
Author(s):  
Eduardo Tolosa ◽  
Georg Ebersbach ◽  
Joaquim J. Ferreira ◽  
Olivier Rascol ◽  
Angelo Antonini ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Impact Assessment ◽  
Real World ◽  
European Countries ◽  
Life Questionnaire ◽  
Motor Symptoms ◽  
Non Motor Symptoms

Background: A greater understanding of the everyday experiences of people with Parkinson’s disease (PD) and their carers may help improve clinical practice. Objective: The Parkinson’s Real-world Impact assesSMent (PRISM) study evaluated medication use, health-related quality of life (HRQoL) and the use of healthcare resources by people with PD and their carers. Methods: PRISM is an observational cross-sectional study, in which people with PD and their carers completed an online survey using structured questionnaires, including the Parkinson’s Disease Quality of Life Questionnaire (PDQ-39), Non-Motor Symptoms Questionnaire (NMSQuest) and Zarit Burden Interview (ZBI). Results: Data were collected from 861 people with PD (mean age, 65.0 years; mean disease duration, 7.7 years) and 256 carers from six European countries. People with PD reported a large number of different co-morbidities, non-motor symptoms (mean NMSQuest score, 12.8), and impaired HRQoL (median PDQ-39 summary score, 29.1). Forty-five percent of people with PD reported at least one impulse control behaviour. Treatment patterns varied considerably between different European countries. Levodopa was taken in the last 12 months by 85.9% of participants, and as monotherapy by 21.8% . Carers, who were mostly female (64.8%) and the partner/spouse of the person with PD (82.1%), reported mild to moderate burden (mean ZBI total score, 26.6). Conclusions: The PRISM study sheds light on the lives of people with PD and those who care for them, re-emphasising the many challenges they face in everyday life. The study also provides insights into the current treatment of PD in Europe.

scholarly journals Study of cognitive impairment and genetic polymorphism of SLC41A1 (rs11240569 allele) in Parkinson’s disease in Upper Egypt: case-control study

2021 ◽  
Vol 57 (1) ◽  
Author(s):  
Hamdy N. El-Tallawy ◽  
Tahia H. Saleem ◽  
Wafaa M. Farghaly ◽  
Heba Mohamed Saad Eldien ◽  
Ashraf Khodaery ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Parkinson's Disease ◽  
Cognitive Impairment ◽  
Case Control Study ◽  
Case Control ◽  
Control Group ◽  
Motor Symptoms ◽  
And Control ◽  
Non Motor Symptoms ◽  
Control Study

Abstract Background Parkinson’s disease is one of the neurodegenerative disorders that is caused by genetic and environmental factors or interaction between them. Solute carrier family 41 member 1 within the PARK16 locus has been reported to be associated with Parkinson’s disease. Cognitive impairment is one of the non-motor symptoms that is considered a challenge in Parkinson’s disease patients. This study aimed to investigate the association of rs11240569 polymorphism; a synonymous coding variant in SLC41A1 in Parkinson’s disease patients in addition to the assessment of cognitive impairment in those patients. Results In a case -control study, rs11240569 single nucleotide polymorphisms in SLC41A1, genes were genotyped in 48 Parkinson’s disease patients and 48 controls. Motor and non-motor performance in Parkinson's disease patients were assessed by using the Movement Disorder Society-Sponsored Revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS). The genotype and allele frequencies were compared between the two groups and revealed no significant differences between case and control groups for rs11240569 in SLC41A1 gene with P value .523 and .54, respectively. Cognition was evaluated and showed the mean ± standard deviation (SD) of WAIS score of PD patients 80.4 ± 9.13 and the range was from 61 to 105, in addition to MMSE that showed mean ± SD 21.96 ± 3.8. Conclusion Genetic testing of the present study showed that rs11240569 polymorphism of SLC41A1 gene has no significant differences in distributions of alleles and genotypes between cases and control group, in addition to cognitive impairment that is present in a large proportion of PD patients and in addition to the strong correlation between cognitive impairment and motor and non-motor symptoms progression.

Sign in / Sign up

Export Citation Format

Share Document